Bad Behaviour by Pharma, and Unforeseen Consequences
This is a must-read for anyone interested in the ethics of drug development and clinical trials.
It explores how genuinely bad behaviour on the part of pharmaceutical companies can lead to overreaction by journalists and the public, sometimes with tragic consequences.
By Matthew Herper, writing for Forbes.com: How Marketing And Media Muddled The Truth About The Heart Drug Vytorin
Big bad drug companies make it easy to fall into a kind of conspiracy-thinking mentality. If Roche and Glaxo are going to behave like lying, data-burying scoundrels, their drugs must be useless, right? But, because medicines have to prove themselves in both a regulatory gauntlet and the market, that’s not always so. And we can be misled by that kind of thinking….
Research Ethics Blog 